Mir-205 has also been shown to promote tumor proliferation by targeting estrogen-related receptor-γ in endometrial carcinoma and contributes to paclitaxel resistance and progression of endometrial carcinoma by downregulating FOXO1, a tumor suppressor [41,42]. This evidence concerns the gene FOXO1 and neoplasm.